Soft tissue sarcomas arising in the retroperitoneal space in children a report from the intergroup rhabdomyosarcoma study (IRS) committee

William M. Crist, A. Beverly Raney, Melvin Tefft, Ruth Heyn, Daniel M. Hays, William Newton, Mohan Beltangady, Harold M. Maurer

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

One hundred one eligible children with soft‐tissue sarcomas arising within the retroperitoneal space have been registered on Intergroup Rhabdomyosarcoma Study Committee (IRS) studies I and II and followed for at least 2 years or until death. The most common presenting symptoms and signs were pain in the abdomen or lower extremities, and/or an abdominal mass, usually noted by a parent or a physician seeing the child for other complaints. The median age at diagnosis was 6.5 years and the sex ratio (M/F) 1.7:1. Histologic types were embryonal or botryoid rhabdomyosarcoma (RMS) in 58 patients, alveolar RMS in 8, pleomorphic RMS in 2, undifferentiated sarcoma in 20, extraosseous Ewing's sarcoma in 4 and unspecified sarcoma in 9. Median tumor size was 10 cm, significantly larger than the 7.5 cm noted in the IRS studies as a whole (P < 0.05). One patient had complete tumor removal (Group I); 12 had grossly complete removal with microscopic residual tumor (Group II). Fifty‐one patients had residual local tumor after biopsy or partial resection (Group III) and 37 patients had distant metastases at diagnosis (Group IV). Treatment included surgery, radiation therapy (RT) and combination chemotherapy with vincristine and actinomycin D with or without cyclophosphamide and Adriamycin (doxorubicin) according to protocol. Thirty‐nine of 99 patients (39%) had major difficulties in the delivery of specified RT. Seventy patients received sufficient therapy to be evaluable for treatment response. Forty‐one (58%) achieved a complete remission and 16 (23%) achieved partial remission. Twenty‐four of 41 children (59%) achieving a CR have relapsed. The proportion of children who remained relapse‐free at 2 and 3 years of follow‐up was 44% or 42%, respectively. Overall, 40 children have developed recurrent sarcoma and the median disease‐free interval and overall survival times were 54 and 88 weeks, respectively. Most children experienced severe myelosuppression; there were three early deaths from infection which occurred during granulocytopenic periods. One third of the patients experienced cystitis. Children with soft‐tissue sarcomas arising in the retroperitoneal space have a poor prognosis associated with large tumors which, because of location and/or extent (Groups III or IV), are unresectable and difficult to treat. Cancer 56: 2125‐2132, 1985.

Original languageEnglish (US)
Pages (from-to)2125-2132
Number of pages8
JournalCancer
Volume56
Issue number8
DOIs
StatePublished - Oct 15 1985

Fingerprint

Retroperitoneal Space
Rhabdomyosarcoma
Sarcoma
Residual Neoplasm
Doxorubicin
Neoplasms
Radiotherapy
Alveolar Rhabdomyosarcoma
Ewing's Sarcoma
Cystitis
Sex Ratio
Dactinomycin
Vincristine
Combination Drug Therapy
Abdomen
Cyclophosphamide
Signs and Symptoms
Lower Extremity
Therapeutics
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Soft tissue sarcomas arising in the retroperitoneal space in children a report from the intergroup rhabdomyosarcoma study (IRS) committee. / Crist, William M.; Raney, A. Beverly; Tefft, Melvin; Heyn, Ruth; Hays, Daniel M.; Newton, William; Beltangady, Mohan; Maurer, Harold M.

In: Cancer, Vol. 56, No. 8, 15.10.1985, p. 2125-2132.

Research output: Contribution to journalArticle

Crist, William M. ; Raney, A. Beverly ; Tefft, Melvin ; Heyn, Ruth ; Hays, Daniel M. ; Newton, William ; Beltangady, Mohan ; Maurer, Harold M. / Soft tissue sarcomas arising in the retroperitoneal space in children a report from the intergroup rhabdomyosarcoma study (IRS) committee. In: Cancer. 1985 ; Vol. 56, No. 8. pp. 2125-2132.
@article{0bc0ffb1a0e54bdd840273a17506d100,
title = "Soft tissue sarcomas arising in the retroperitoneal space in children a report from the intergroup rhabdomyosarcoma study (IRS) committee",
abstract = "One hundred one eligible children with soft‐tissue sarcomas arising within the retroperitoneal space have been registered on Intergroup Rhabdomyosarcoma Study Committee (IRS) studies I and II and followed for at least 2 years or until death. The most common presenting symptoms and signs were pain in the abdomen or lower extremities, and/or an abdominal mass, usually noted by a parent or a physician seeing the child for other complaints. The median age at diagnosis was 6.5 years and the sex ratio (M/F) 1.7:1. Histologic types were embryonal or botryoid rhabdomyosarcoma (RMS) in 58 patients, alveolar RMS in 8, pleomorphic RMS in 2, undifferentiated sarcoma in 20, extraosseous Ewing's sarcoma in 4 and unspecified sarcoma in 9. Median tumor size was 10 cm, significantly larger than the 7.5 cm noted in the IRS studies as a whole (P < 0.05). One patient had complete tumor removal (Group I); 12 had grossly complete removal with microscopic residual tumor (Group II). Fifty‐one patients had residual local tumor after biopsy or partial resection (Group III) and 37 patients had distant metastases at diagnosis (Group IV). Treatment included surgery, radiation therapy (RT) and combination chemotherapy with vincristine and actinomycin D with or without cyclophosphamide and Adriamycin (doxorubicin) according to protocol. Thirty‐nine of 99 patients (39{\%}) had major difficulties in the delivery of specified RT. Seventy patients received sufficient therapy to be evaluable for treatment response. Forty‐one (58{\%}) achieved a complete remission and 16 (23{\%}) achieved partial remission. Twenty‐four of 41 children (59{\%}) achieving a CR have relapsed. The proportion of children who remained relapse‐free at 2 and 3 years of follow‐up was 44{\%} or 42{\%}, respectively. Overall, 40 children have developed recurrent sarcoma and the median disease‐free interval and overall survival times were 54 and 88 weeks, respectively. Most children experienced severe myelosuppression; there were three early deaths from infection which occurred during granulocytopenic periods. One third of the patients experienced cystitis. Children with soft‐tissue sarcomas arising in the retroperitoneal space have a poor prognosis associated with large tumors which, because of location and/or extent (Groups III or IV), are unresectable and difficult to treat. Cancer 56: 2125‐2132, 1985.",
author = "Crist, {William M.} and Raney, {A. Beverly} and Melvin Tefft and Ruth Heyn and Hays, {Daniel M.} and William Newton and Mohan Beltangady and Maurer, {Harold M.}",
year = "1985",
month = "10",
day = "15",
doi = "10.1002/1097-0142(19851015)56:8<2125::AID-CNCR2820560841>3.0.CO;2-D",
language = "English (US)",
volume = "56",
pages = "2125--2132",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Soft tissue sarcomas arising in the retroperitoneal space in children a report from the intergroup rhabdomyosarcoma study (IRS) committee

AU - Crist, William M.

AU - Raney, A. Beverly

AU - Tefft, Melvin

AU - Heyn, Ruth

AU - Hays, Daniel M.

AU - Newton, William

AU - Beltangady, Mohan

AU - Maurer, Harold M.

PY - 1985/10/15

Y1 - 1985/10/15

N2 - One hundred one eligible children with soft‐tissue sarcomas arising within the retroperitoneal space have been registered on Intergroup Rhabdomyosarcoma Study Committee (IRS) studies I and II and followed for at least 2 years or until death. The most common presenting symptoms and signs were pain in the abdomen or lower extremities, and/or an abdominal mass, usually noted by a parent or a physician seeing the child for other complaints. The median age at diagnosis was 6.5 years and the sex ratio (M/F) 1.7:1. Histologic types were embryonal or botryoid rhabdomyosarcoma (RMS) in 58 patients, alveolar RMS in 8, pleomorphic RMS in 2, undifferentiated sarcoma in 20, extraosseous Ewing's sarcoma in 4 and unspecified sarcoma in 9. Median tumor size was 10 cm, significantly larger than the 7.5 cm noted in the IRS studies as a whole (P < 0.05). One patient had complete tumor removal (Group I); 12 had grossly complete removal with microscopic residual tumor (Group II). Fifty‐one patients had residual local tumor after biopsy or partial resection (Group III) and 37 patients had distant metastases at diagnosis (Group IV). Treatment included surgery, radiation therapy (RT) and combination chemotherapy with vincristine and actinomycin D with or without cyclophosphamide and Adriamycin (doxorubicin) according to protocol. Thirty‐nine of 99 patients (39%) had major difficulties in the delivery of specified RT. Seventy patients received sufficient therapy to be evaluable for treatment response. Forty‐one (58%) achieved a complete remission and 16 (23%) achieved partial remission. Twenty‐four of 41 children (59%) achieving a CR have relapsed. The proportion of children who remained relapse‐free at 2 and 3 years of follow‐up was 44% or 42%, respectively. Overall, 40 children have developed recurrent sarcoma and the median disease‐free interval and overall survival times were 54 and 88 weeks, respectively. Most children experienced severe myelosuppression; there were three early deaths from infection which occurred during granulocytopenic periods. One third of the patients experienced cystitis. Children with soft‐tissue sarcomas arising in the retroperitoneal space have a poor prognosis associated with large tumors which, because of location and/or extent (Groups III or IV), are unresectable and difficult to treat. Cancer 56: 2125‐2132, 1985.

AB - One hundred one eligible children with soft‐tissue sarcomas arising within the retroperitoneal space have been registered on Intergroup Rhabdomyosarcoma Study Committee (IRS) studies I and II and followed for at least 2 years or until death. The most common presenting symptoms and signs were pain in the abdomen or lower extremities, and/or an abdominal mass, usually noted by a parent or a physician seeing the child for other complaints. The median age at diagnosis was 6.5 years and the sex ratio (M/F) 1.7:1. Histologic types were embryonal or botryoid rhabdomyosarcoma (RMS) in 58 patients, alveolar RMS in 8, pleomorphic RMS in 2, undifferentiated sarcoma in 20, extraosseous Ewing's sarcoma in 4 and unspecified sarcoma in 9. Median tumor size was 10 cm, significantly larger than the 7.5 cm noted in the IRS studies as a whole (P < 0.05). One patient had complete tumor removal (Group I); 12 had grossly complete removal with microscopic residual tumor (Group II). Fifty‐one patients had residual local tumor after biopsy or partial resection (Group III) and 37 patients had distant metastases at diagnosis (Group IV). Treatment included surgery, radiation therapy (RT) and combination chemotherapy with vincristine and actinomycin D with or without cyclophosphamide and Adriamycin (doxorubicin) according to protocol. Thirty‐nine of 99 patients (39%) had major difficulties in the delivery of specified RT. Seventy patients received sufficient therapy to be evaluable for treatment response. Forty‐one (58%) achieved a complete remission and 16 (23%) achieved partial remission. Twenty‐four of 41 children (59%) achieving a CR have relapsed. The proportion of children who remained relapse‐free at 2 and 3 years of follow‐up was 44% or 42%, respectively. Overall, 40 children have developed recurrent sarcoma and the median disease‐free interval and overall survival times were 54 and 88 weeks, respectively. Most children experienced severe myelosuppression; there were three early deaths from infection which occurred during granulocytopenic periods. One third of the patients experienced cystitis. Children with soft‐tissue sarcomas arising in the retroperitoneal space have a poor prognosis associated with large tumors which, because of location and/or extent (Groups III or IV), are unresectable and difficult to treat. Cancer 56: 2125‐2132, 1985.

UR - http://www.scopus.com/inward/record.url?scp=0021994739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021994739&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19851015)56:8<2125::AID-CNCR2820560841>3.0.CO;2-D

DO - 10.1002/1097-0142(19851015)56:8<2125::AID-CNCR2820560841>3.0.CO;2-D

M3 - Article

C2 - 3896467

AN - SCOPUS:0021994739

VL - 56

SP - 2125

EP - 2132

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -